Health System Reform Crucial For ATMPs
The difficulties in getting advanced therapies, such as Novartis’ CAR-T therapy Kymriah, to patients have shifted and manufacturing capacity is no longer the biggest issue.
You may also be interested in...
The number of conditional marketing authorization non-renewals could increase.
El Salvador has approved a new law that will establish a new regulatory body responsible for authorizing medicines and setting prices.
NHS England has committed to two pilots on innovative pricing models for advanced therapies under the UK’s new voluntary pricing agreement for new medicines.